IP Library Granted Patent US 8,535,894
Granted Patent B2
US 8,535,894 · App. 13/610,009 · Granted Sep 17, 2013

Antibody complexes and methods for immunolabeling

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,535,894
App. No.
13/610,009
Granted
Sep 17, 2013
Kind
B2
Abstract

Provided are labeling reagents and methods for labeling primary antibodies and for detecting a target in a sample using an immuno-labeled complex that comprises a target-binding antibody and one or more labeling reagents. The labeling reagents comprise monovalent antibody fragments or non-antibody monomeric proteins whereby the labeling proteins have affinity for a specific region of the target-binding antibody and are covalently attached to a label. Discrete subsets of labeling reagent and immune-labeled complexes are provided that facilitate the simultaneous detection of multiple targets in a sample-complexes are distinguished by i) a ratio of label to labeling reagent, or ii) a physical property of said label, or iii) a ratio of labeling reagent to said target-binding antibody, or iv) by said target-binding antibody. This is particularly useful for fluorophore labels that can be attached to labeling reagents and subsequently immuno-labeled complexes in ratios for the detection of multiple targets.

Claims (25)

1. A method of manufacturing an isolated labeling reagent, wherein said method comprises the steps of:

a) cleaving an intact anti-region antibody with an enzyme to generate Fab fragments;

b) isolating said anti-region Fab fragments of step a);

c) contacting a matrix comprising intact immunoglobulin proteins or fragments that selectively bind anti-region Fab fragments with a solution comprising said anti-region fragments of step b) wherein said anti-region Fab fragments are immobilized on said matrix;

d) contacting said matrix of step c) with a solution comprising a fluorophore label that contains a reactive group;

e) washing said matrix of step d) to remove unbound label, and;

f) eluting said labeling reagent from said matrix whereby said isolated labeling reagent is manufactured.

2. The method according to claim 1 , wherein said anti-region Fab fragment are selected from the group consisting of anti-Fc antibody fragment, anti-kappa light chain antibody fragment, anti-lambda light chain antibody fragment, and a single chain variable protein fragment.

3. The method according to claim 2 , wherein said fluorophore is selected from the group consisting of a coumarin, a xanthene, a cyanine, a pyrene, a borapolyazaindacene, an oxazine and derivatives thereof.

4. A method of manufacturing an isolated labeling reagent, wherein said method comprises the steps of:

a) contacting a matrix comprising intact immunoglobulin proteins or fragments thereof that selectively bind non-antibody proteins with a solution comprising said non-antibody proteins wherein said non-antibody proteins are immobilized on said matrix;

b) contacting said matrix of step a) with a solution comprising a fluorophore label that contains a reactive group;

c) washing said matrix to remove unbound label, and;

d) eluting said labeling reagent from said matrix whereby said isolated labeling reagent is manufactured that comprises a fluorophore label.

5. The method according to claim 4 , wherein said non-antibody protein is selected from the group consisting of protein G, protein A, protein L, lectin, and derivatives thereof.

6. The method according to claim 5 , wherein said fluorophore is selected from the group consisting of a coumarin, a xanthene, a cyanine, a pyrene, a borapolyazaindacene, an oxazine and derivatives thereof.

7. An isolated labeling reagent made by a process comprising:

a) cleaving an intact anti-region antibody with an enzyme to generate Fab fragments;

b) isolating said anti-region Fab fragments of step a);

c) contacting a matrix comprising intact immunoglobulin proteins or fragments thereof that specifically bind anti-region Fab fragments with a solution comprising said anti-region Fab fragments of step b) wherein said anti-region Fab fragments are immobilized;

d) contacting said matrix of step c) with a solution comprising a fluorophore label that contains a reactive group;

e) washing said matrix to remove unbound label, and;

f) eluting said labeling reagent from said matrix whereby said labeling reagent is manufactured comprising a label and being isolated from other proteins or fragments thereof.

8. The labeling reagent according to claim 7 , wherein said anti-region Fab fragment is selected from the group consisting of anti-Fc antibody fragment, anti-kappa light chain antibody fragment, anti-lambda light chain antibody fragment, and a single chain variable protein fragment.

9. The labeling reagent according to claim 8 , wherein said fluorophore is selected from the group consisting of a coumarin, a xanthene, a cyanine, a pyrene, a borapolyazaindacene, an oxazine and derivatives thereof.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 8, 2012
From: ARCHER, ROBERT; BEECHEM, JOSEPH; HAGEN, DAVID; HAUGLAND, RICHARD; HAUGLAND, ROSARIA
To: MOLECULAR PROBES, INC.
Reel/Frame 029090/0773 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 8, 2012
From: MOLECULAR PROBES, INC.
To: LIFE TECHNOLOGIES CORPORATION
Reel/Frame 029090/0819 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 8, 2012
From: BEECHEM, JOSEPH
To: LIFE TECHNOLOGIES CORPORATION
Reel/Frame 029090/0857 →
MERGER Recorded Oct 8, 2012
From: INVITROGEN CORPORATION
To: LIFE TECHNOLOGIES CORPORATION
Reel/Frame 029090/0888 →